ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0837

Risk of New Proteinuria in Next Ten Years in SLE

Michelle Petri1, Ilayda Demirayak2, Andrea Fava3, Daniel Goldman1 and Laurence Magder4, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Istanbul University, Istanbul, Turkey, 3Johns Hopkins University, Baltimore, MD, 4University of Maryland, Baltimore, Baltimore, MD

Meeting: ACR Convergence 2025

Keywords: Diagnostic criteria, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

Session Type: Abstract Session

Session Time: 3:00PM-3:15PM

Background/Purpose: The current 2024 ACR Lupus Nephritis guidelines recommend checking the urine protein to creatinine ratio (UPCR) every 6-12 months. Early recognition of lupus nephritis (LN), though, would lead to earlier introduction of treatment and better outcomes. A risk formula to project a patient’s risk of incident proteinuria within 10 years of SLE diagnosis would allow more frequent UPCR checks in the highest risk population.

Methods: The analysis is based on 1,418 members of the Hopkins Lupus Cohort who had been followed for longer than one year since SLE diagnosis. Subjects who developed proteinuria before or in the year of SLE diagnosis were excluded. A multivariate equation to predict the risk of incident proteinuria was developed using a forward-stepwise approach, considering each of the univariate associates in turn, and adding the variable that led to the greatest reduction in Akaike’s Information Criterion (AIC).

Results: Univariate associates of incident (new) proteinuria after 1 year from SLE diagnosis are shown in Table 1. Table 2 shows the multivariate predictors of incident proteinuria. Major risk factors included non-Caucasian race and anti-Sm. Moderate risk factors included male sex, anti-RNP, anti-dsDNA, and low C4 at the time of SLE diagnosis. Based on this model we estimated the 10-year risk as a function of the number of risk factors a patient has (Table 3). A person with no risk factors has only a 2.6% chance of developing proteinuria in 10 years, whereas a person with all 8 risk factors has a 49% chance.

Conclusion: We built a risk score for proteinuria in the next 10 years that would allow clinicians to identify a high risk subset of SLE patients to target for more frequent measurement of urine protein to creatinine AND to consider earlier renal biopsy at even low levels of proteinuria. The risk factors include well accepted demographic variables (non-Caucasian race, male sex) and serologic tests that are easily available (low C4, anti-Sm, anti-RNP and anti-dsDNA).

Supporting image 1Table 1. Association between various manifestations in the first year after SLE diagnosis and eventual incidence proteinuria

Supporting image 2Table 2. Multivariable model to predict incident proteinuria

Supporting image 3Table 3. Risk of incident proteinuria within 10 years of SLE diagnosis as a function of the number of risk factors (Each row in Table 2 counts as 1 risk factor except Anti-Sm and “Other” race which count as 2 risk factors)


Disclosures: M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 2, 5, Autolus, 2, Bain Capital, 2, Baobab Therapeutics, 2, Biocryst, 2, Biogen, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI Clinical Trial and Consulting Services, 2, CVS Health, 2, Dualitybio, 2, Eli Lilly, 2, 5, EMD Serono, 2, Emergent, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 2, Janssen, 5, Kezar Life Sciences, 2, Kira Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, Ono Pharma, 2, PPD Development, 2, Proviant, 2, Regeneron, 2, Seismic Therapeutic, 2, Senti Biosciences, 2, Sinomab Biosciences, 2, Steritas, 2, Takeda, 2, Tenet Medicines, 2, TG Therapeutics, 2, UCB, 2, Variant Bio, 2, Worldwide Clinical Trials, 2, Zydus, 2; I. Demirayak: None; A. Fava: Artiva, 2, AstraZeneca, 1, 2, Bain Capital, 2, Biogen, 1, Bristol-Myers Squibb(BMS), 2, Exagen, 5, 9, Quotient Therapeutics, 2, UCB, 6, Zenas, 2; D. Goldman: None; L. Magder: None.

To cite this abstract in AMA style:

Petri M, Demirayak I, Fava A, Goldman D, Magder L. Risk of New Proteinuria in Next Ten Years in SLE [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/risk-of-new-proteinuria-in-next-ten-years-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-new-proteinuria-in-next-ten-years-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology